Discover
Stelara (ustekinumab) / J&J; Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko KirinEMBRACE 1: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) - Mar 12, 2020 - P3; N=120; Not yet recruiting; Sponsor: LEO Pharma
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimAbbVie’s Skyrizi expected to rock local psoriasis treatment market (Korea Biomedical Review) - Mar 11, 2020 - "AbbVie’s Skyrizi (ingredient: risankizumab), an interleukin-23 (IL-23) inhibitor, has passed the local health authorities’ reimbursement review three months after winning the marketing license in Korea....Armed with excellent data, Skyrizi recently passed the review of the Health and Insurance Review and Assessment Service (HIRA)’s Pharmaceutical Reimbursement Evaluation Committee."
Cosentyx (secukinumab) / NovartisINVIGORATE 2: Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) - Mar 12, 2020 - P3; N=380; Recruiting; Sponsor: Novartis Pharmaceuticals; Not yet recruiting --> Recruiting
Tremfya (guselkumab) / J&JJanssen launched Tremfya, event [Google translation] (Pharmabiz) - Mar 9, 2020 - "Janssen Immuno is putting all his chips to Tremfya, his new product to treat severe psoriasis. It is in this context that last week the company held an event in the Escondida de Dorrego - Palermo - to present the product to the medical community of Argentina and Chile."
Siliq (brodalumab) / Bausch Health, Leo Pharma, Kyowa Hakko KirinAdjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight (clinicaltrials.gov) - Mar 12, 2020 - P4; N=384; Not yet recruiting; Sponsor: LEO PharmaClinical • New P4 trial
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimPlaque psoriasis: Reimbursement for risankizumab [Google translation] (Corriere Nazionale) - Mar 8, 2020 - "The Italian Medicines Agency (Aifa) has approved the reimbursement in Italy of risankizumab for the treatment of moderate to severe plaque psoriasis in adult patients candidates for systemic therapy. Risankizumab can be administered by two subcutaneous injections every 12 weeks, after two starting doses administered at week 0 and week 4."
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimAbbVie announces new formulary listings for Skyrizi in the treatment of moderate to severe plaque psoriasis (Benzinga) - Mar 11, 2020 - "AbbVie...announced today that SKYRIZI® (risankizumab) is now listed on the formularies of the Non-Insured Health Benefits program (NIHB) and the province of Manitoba for the treatment of moderate to severe plaque psoriasis. This announcement comes just three months after AbbVie successfully reached an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA), bringing a much-needed treatment to patients living with psoriasis."
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimPublic consultation for inclusion of new medication for psoriasis in SUS open on CONITEC website [Google translation] (PRNewswire) - Mar 13, 2020 - "The National Commission for the Incorporation of Technologies in the Unified Health System (CONITEC) is open to public consultation to receive contributions from the population to assess the incorporation by SUS of risanquizumab for the treatment of adult patients with moderate to severe plaque psoriasis, candidates for phototherapy or systemic treatment."
JTE-451 / Japan Tobacco, OrphagenIMPACT-PS: Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Mar 9, 2020 - P2; N=152; Completed; Sponsor: Akros Pharma Inc.; Active, not recruiting --> Completed; Trial completion date: Jul 2020 --> Feb 2020
